ToxiPharm LLC

ToxSignal

Clinical Toxicology Intelligence

Issue

#11

July 2026

77.5% of Patients in the Philadelphia Medetomidine Series Required ICU Admission. The System Is Not Ready.

A multicenter Philadelphia series of 209 patients with medetomidine-associated fentanyl withdrawal, published this week in Journal of Addiction Medicine, shows that this withdrawal syndrome carries a severity profile most facilities are not equipped for. Of the 209 cases: 77.5% required ICU admission, 20.1% required intubation, and 73.7% received IV dexmedetomidine infusions after standard opioid withdrawal management was insufficient to control symptoms. This is not a series of people who arrived critically ill from overdose. It is a series of people who presented in withdrawal and deteriorated because the protocols in place were built for a different physiology.

The supply context makes these numbers more urgent, not less. Philadelphia street drug samples have shifted from 29% to 87% medetomidine-positive over recent surveillance periods, while xylazine prevalence in the same samples fell from 97% to 42%. Massachusetts now reports medetomidine in every county. The DEA documented the same displacement pattern nationally in its May 2026 advisory. Medetomidine is not emerging alongside xylazine in most active supply networks; in many areas it is replacing it, and the withdrawal syndrome it produces is more autonomically severe with a faster onset.

The management picture from the series confirms what two other 2026 publications describe: oral and transdermal clonidine at above-label doses is first-line, but refractory nausea and vomiting frequently prevent enteral therapy from working, and IV dexmedetomidine at infusion rates exceeding standard ICU sedation protocols becomes the fallback. Opioid withdrawal and any other concurrent substance withdrawal has to be managed simultaneously and separately.

Multicenter Philadelphia series, n=209. J Addict Med. 2026. PMID 40747932.  ·  Zimmerman DE, et al. Am J Health Syst Pharm. 2026. doi:10.1093/ajhp/zxag141.  ·  DEA Public Safety Advisory, May 12, 2026.

Deadline: July 27, 2026 — 8 Days

SAMHSA MAT-PDOA Grant (TI-26-008): $68.25M Available, Applications Close July 27.

SAMHSA's Medication-Assisted Treatment for Prescription Drug and Opioid Addiction NOFO (TI-26-008) closes Monday, July 27 as part of a broader $281 million package announced July 6. Award ceiling is $750,000 per grantee; approximately 91 awards are expected. Eligible applicants include OTPs, community mental health centers, and Federally Qualified Health Centers seeking to expand MOUD access.

Grant applications in this cycle typically require drug testing protocols, MOUD monitoring plans, and outcome measures. If an OTP or treatment program in your network has not confirmed whether an application is in flight, this week is the last window to check. Details at samhsa.gov.

Legislation: MOTAA 2.0 (Reintroduced June 2026)

Pharmacy Methadone Dispensing Bill Is Dividing the OTP Field. NABH Is Pushing Back.

The Modernizing Opioid Treatment Access Act 2.0 (Markey/Paul), reintroduced in June, would permit pharmacy dispensing of methadone for OUD in liquid and dissolvable-only formulations, establish e-prescribing pathways, and place oversight exclusively with DEA rather than SAMHSA. The National Association for Behavioral Health (NABH) and a number of OTP operators are pushing back, citing concerns about diversion risk and the loss of the structured treatment framework OTPs provide. For programs that currently offer methadone: watch how this moves, particularly the question of whether DEA-only oversight changes the inspection and compliance landscape your program operates under.

UPDATED CLINICAL GUIDANCE / ADLM 2026

ADLM Updates Emergency Department Toxicology Testing Guidance for the First Time Since 2003. Fentanyl and Oxycodone Are Now Core.

The Association for Diagnostics and Laboratory Medicine previewed two new guidance documents at its July meeting replacing the organization's 2003 emergency department toxicology testing recommendations. The updated core urine panel recommendation adds fentanyl and oxycodone to a list that previously did not include either: amphetamines, benzodiazepines, cocaine metabolite, fentanyl, opiates, and oxycodone. The 2003 guideline predates the fentanyl crisis by more than a decade and did not reflect what emergency departments actually encounter in 2026.

The significance for clinical practice: emergency departments following the prior guidance were not recommending fentanyl-specific testing as standard. A urine panel that catches opiates (morphine, codeine) through immunoassay cross-reactivity will frequently miss fentanyl, which does not cross-react with most standard opiate immunoassays. Adding fentanyl to the core recommendation is a direct response to that analytical gap.

ADLM 2026 ED toxicology testing guidance preview. CAP Today. July 2026. Full guidance documents pending publication.